[ Sentien Biotechnologies raises $12M in Series A ]

Sentien Biotechnologies has raised $12 million in Series A funding.

Founded in 2008, Sentien Biotechnologies  is a preclinical stage regenerative medicine company that is developing cell based therapies for critical care.

The Series A round will be used to fund initial clinical development of Sentien’s SBI-101 for the treatment of acute kidney injury (AKI).

Funding  Series A
Founded  2008
Country  USA
City  Medford, Massachusetts
Founder / CEO  Brian Miller
Deal Size  $12M
Investors  BioInnovation
 Mass Medical Angels
 MBL Venture Capital
 Chiesi Ventures
 Boehringer Ingelheim Venture Fund
Previous Investors  /

[adyen action=”checkout_button”]